Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,739 stopped studies mapped to Lymphoma and descendants · 89% state a reason
Over the 1,739 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd…(BIOSELECT) | Phase 1 / Phase 2 | withdrawn | Sep 14, 2022 | AHS Cancer Control Alberta | Contractual Issues | Other (stated, no rule matched) |
| NCT03786926 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Phase 1 | terminated | Dec 26, 2018 | Hutchmed | 2018-689-00US1 has been halted by HUTCHMED based on strategic evaluation of the clinical… | Sponsor / business decision |
| NCT05010369 | DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)(DOLPHIN-VIVO) | N/A | terminated | Aug 18, 2021 | University of Exeter | Funding extension not granted | Funding |
| NCT05442580 | CART-38 in Adult AML and MM Patients | Phase 1 | terminated | Jul 5, 2022 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05121103 | A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative… | Phase 1 | terminated | Nov 16, 2021 | Epizyme, Inc. | Strategic business decision | Sponsor / business decision |
| NCT04735471 | A Phase 1 Study of ADI-001 in B Cell Malignancies(GLEAN-1) | Phase 1 | terminated | Feb 3, 2021 | Adicet Therapeutics | Terminated - Halted Prematurely | Other (stated, no rule matched) |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072… | Phase 1 / Phase 2 | terminated | Jan 6, 2017 | CytomX Therapeutics | Sponsor's decision | Sponsor / business decision |
| NCT05027594 | Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Aug 30, 2021 | Nerviano Medical Sciences | The decision is not based on emerging safety or efficacy concerns but on strategic reasons related… | Safety / toxicity |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel… | N/A | withdrawn | Nov 3, 2021 | Case Comprehensive Cancer Center | Study closed prior to enrollment of first participant | Enrollment / accrual |
| NCT04986865 | A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell…(PROBE) | Phase 1 | terminated | Aug 3, 2021 | Antengene Biologics Limited | It is due to the recent changes in the competitor landscape and strategic consideration | Sponsor / business decision |
| NCT05265975 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With…(SWATCH) | Phase 1 / Phase 2 | terminated | Mar 4, 2022 | Antengene Corporation | The adjustment of the sponsor's research and development strategy | Sponsor / business decision |
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression…(BOSS) | Phase 2 | withdrawn | Feb 21, 2025 | AstraZeneca | AstraZeneca has made the decision to cancel the trial. | Other (stated, no rule matched) |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute… | Early Phase 1 | terminated | Jul 26, 2019 | Institute of Hematology & Blood Diseases Hospital, China | Due to adjustments in the company's strategy, the research and development of this project has been… | Sponsor / business decision |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | Phase 1 / Phase 2 | terminated | May 9, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Poor accrual | Enrollment / accrual |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Phase 2 | terminated | Dec 6, 2019 | University of Miami | Investigator Decision | Investigator |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | Gilead Sciences | Study terminated early due to the magrolimab program discontinuation. | Other (stated, no rule matched) |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT05788289 | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | Phase 2 | terminated | Mar 28, 2023 | Memorial Sloan Kettering Cancer Center | Slow accrual rate | Enrollment / accrual |
| NCT02811679 | A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin… | Phase 2 | terminated | Jun 23, 2016 | Massachusetts General Hospital | Study closed early due to slow accrual | Enrollment / accrual |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | Phase 2 | withdrawn | May 18, 2010 | Situs Cancer Research Center | Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche… | Drug supply |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed,… | Phase 1 | terminated | May 19, 2021 | Mayo Clinic | Low/slow accrual - did not proceed to Phase 2 | Enrollment / accrual |
| NCT00626444 | Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL) | Phase 2 | terminated | Feb 29, 2008 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04570631 | Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in… | Phase 1 | terminated | Sep 30, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and… | — | withdrawn | Jan 5, 2021 | Memorial Sloan Kettering Cancer Center | Lack of potential participants given the other treatment options currently available to people | Other (stated, no rule matched) |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Jun 21, 2019 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated. | Enrollment / accrual |
| NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial… | Early Phase 1 | terminated | Nov 17, 2016 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT04556266 | A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for… | Phase 1 | withdrawn | Sep 21, 2020 | Memorial Sloan Kettering Cancer Center | No patients were enrolled to this study since being open to enrollment. Due to changes in available… | Enrollment / accrual |
| NCT02823327 | Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma | — | terminated | Jul 6, 2016 | AIDS Malignancy Consortium | Poor accrual | Enrollment / accrual |
| NCT05833737 | Corneal Findings in Patients Treated With Belantamab Mafodotin | — | terminated | Apr 27, 2023 | Medical University of Vienna | Study medication market withdrawal by FDA. | Other (stated, no rule matched) |
| NCT06290622 | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Phase 1 | withdrawn | Mar 4, 2024 | University of Alabama at Birmingham | Investigator request to no longer pursue this study. Lack of support from drug company. This trial… | Investigator |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in… | Phase 1 | withdrawn | Sep 14, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04217317 | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell… | Phase 2 | terminated | Jan 3, 2020 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | May 19, 2021 | Gilead Sciences | This study was terminated early due to the Sponsor's decision to discontinue development of the… | Sponsor / business decision |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic… | Phase 1 | terminated | May 11, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Insufficient accrual over 12 mo period | Enrollment / accrual |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel… | Phase 2 | withdrawn | Sep 20, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Funding discontinued | Funding |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20… | Phase 1 | terminated | Jul 9, 2020 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT04668365 | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With… | Phase 2 | suspended | Dec 16, 2020 | Henan Cancer Hospital | Data in analysis | Other (stated, no rule matched) |
| NCT00848328 | Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma | Phase 2 | terminated | Feb 20, 2009 | University of California, Davis | Poor accrual | Enrollment / accrual |
| NCT06941688 | Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for… | Phase 2 | terminated | Apr 24, 2025 | Seoul National University Hospital | slow recruitment | Enrollment / accrual |
| NCT02875223 | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory… | Phase 1 | terminated | Aug 23, 2016 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04047797 | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell… | Phase 2 | terminated | Aug 7, 2019 | M.D. Anderson Cancer Center | Administratively Complete 75%\<Participants | Other (stated, no rule matched) |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed… | Phase 1 | terminated | Apr 3, 2018 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. A new study in CLL patients is planned. | Other (stated, no rule matched) |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA… | Phase 2 | terminated | Aug 3, 2018 | Memorial Sloan Kettering Cancer Center | Low accrual | Enrollment / accrual |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple… | Phase 1 / Phase 2 | terminated | May 21, 2021 | University of Maryland, Baltimore | The study was terminated due to FDA withdrawal of the drug and lack of enrollment with available… | Enrollment / accrual |
| NCT03187210 | Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas(BAL) | Phase 1 / Phase 2 | suspended | Jun 14, 2017 | Insel Gruppe AG, University Hospital Bern | low accrual | Enrollment / accrual |
| NCT03871829 | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously… | Phase 2 | terminated | Mar 12, 2019 | Janssen Research & Development, LLC | The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 4, 2025source: clinicaltrials